Drugs.com New Drug Approvals · 4/1/2026
FDA Approves Foundayo (orforglipron), the Only GLP-1 Pill for Weight Loss That Can be Taken Any Time of Day Without Food or Water Restrictions
INDIANAPOLIS, April 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical...
Why this is tracked
This item matched GLP-1, Medicare, Part D, CMS, FDA, coverage, pricing, prior authorization, or access terms used by the daily monitor.
Read the source
This page summarizes and links to the original source. Use the source article, CMS/FDA notices, plan documents, and clinician guidance for decisions.